FRANKFURT: AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday.
A study with patients diagnosed early enough for the lung tumour to be surgically removed, and who have a mutation of the so-called EGFR gene, found that Tagrisso cut the risk of developing brain metastases by 82%.
The late-stage Phase III trial results – presented at the virtual European Society for Medical Oncology (ESMO) conference over the weekend – underscore the drug’s potential and may encourage a push to diagnose lung cancer earlier for patients to benefit from the drug, Astra said.
According to earlier findings of the same trial known as ADAURA published in May, Tagrisso held back early-stage EGFR…
